Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
A reverse discounted cash flow is not shown for a company with no positive EBITDA.
No positive EBITDA in the recent record, so there is no return on capital to compare against its cost.
Classified from the filings: EBITDA negative in each of the last 2 years.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$663.8M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 8 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -41%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 8 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
EOD close · as of 2026-10-30
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE -41% against ROIC -41% — 0% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is -44.0% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 1.3× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| R&D | 2225.9 | 627.0 | 554.0 | 1084.9 | 1630.6 | 1997.6 | 2786.0 | 2981.4 |
| SG&A | 644.1 | 220.4 | 198.3 | 280.9 | 409.1 | 566.8 | 791.4 | 1095.9 |
| Operating Income | -2769.9 | -747.4 | -652.4 | -1265.8 | -1939.6 | -2464.4 | -3477.4 | -3977.3 |
| Income Tax | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -2959.4 | -1066.6 | -653.5 | -1265.4 | -1886.3 | -2219.9 | -2957.7 | -3650.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on RNA: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2020 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.8M 100.0% | $10.9M 100.0% | $9.6M 100.0% | $9.2M 100.0% | $9.3M 100.0% | $6.8M 100.0% | $2.3M 100.0% | $379K 100.0% |
| Research & Development | $559.2M 2981.4% | $303.6M 2786.0% | $191.0M 1997.6% | $150.4M 1630.6% | $101.2M 1084.9% | $37.6M 554.0% | $14.5M 627.0% | $8.4M 2225.9% |
| Selling, General & Admin | $205.5M 1095.9% | $86.2M 791.4% | $54.2M 566.8% | $37.7M 409.1% | $26.2M 280.9% | $13.5M 198.3% | $5.1M 220.4% | $2.4M 644.1% |
| Total Operating Expenses | $764.7M 4077.3% | $389.8M 3577.4% | $245.2M 2564.4% | $188.1M 2039.6% | $127.4M 1365.8% | $51.1M 752.4% | $19.7M 847.4% | $10.9M 2869.9% |
| Operating Income | -$745.9M -3977.3% | -$378.9M -3477.4% | -$235.6M -2464.4% | -$178.9M -1939.6% | -$118.1M -1265.8% | -$44.3M -652.4% | -$17.3M -747.4% | -$10.5M -2769.9% |
| Interest Expense | — | — | — | $0 0.0% | $0 0.0% | $209K 3.1% | $7.4M 318.5% | $718K 189.4% |
| Other Income (Expense), net | $61.3M 326.9% | $56.6M 519.7% | $23.4M 244.5% | $4.9M 53.3% | $42K 0.5% | -$78K -1.1% | -$7.4M -319.2% | -$718K -189.4% |
| Pretax Income | -$684.6M -3650.4% | -$322.3M -2957.7% | -$212.2M -2219.9% | — | — | — | — | — |
| Income Tax Expense | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | — |
| Net Income | -$684.6M -3650.4% | -$322.3M -2957.7% | -$212.2M -2219.9% | -$174.0M -1886.3% | -$118.0M -1265.4% | -$44.4M -653.5% | -$24.7M -1066.6% | -$11.2M -2959.4% |
| Per Share | ||||||||
| EPS (Basic) | -$4.97 | -$2.89 | -$2.91 | -$3.34 | -$2.85 | -$2.05 | — | — |
| EPS (Diluted) | -$4.97 | -$2.89 | -$2.91 | -$3.34 | -$2.85 | -$2.05 | — | — |
| Weighted Avg Shares (Basic) | 137.7M | 111.6M | 73.0M | 52.2M | 41.4M | 21.7M | — | — |
| Weighted Avg Shares (Diluted) | 137.7M | 111.6M | 73.0M | 52.2M | 41.4M | 21.7M | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 16 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMRN | $509M | — | — | 2.4× | -6.5% | 56.6% | -18.2% | -8.4% | -8.4% | — | 9 |
| GYRE | $484M | 228.0× | 31.1× | 4.2× | 10.2% | 95.4% | 8.5% | 15.8% | 15.8% | -3.5× | 7 |
| SVA | $465M | — | — | 1.2× | 6.8% | 67.9% | -51.5% | -4.5% | -4.0% | — | 2 |
| CRMD | $447M | 2.8× | 2.0× | 1.4× | 617% | 88.5% | 52.3% | 40.2% | 40.2% | -1.0× | 24 |
| VREOF | $385M | — | 18.8× | 1.4× | 170% | 47.3% | -25.3% | -22.2% | -22.2% | -6.8× | — |
| EBS | $349M | 7.3× | 3.6× | 0.5× | -28.8% | 56.1% | 7.1% | 10.1% | 4.8% | 1.9× | 29 |
| QTTB | $265M | 3.7× | 12.6× | 4.9× | — | — | 55.5% | 71.0% | 71.0% | -2.8× | 3 |
| ELTP | $248M | 7.7× | 4.3× | 1.7× | 77.1% | 50.4% | 30.1% | 45.4% | 45.4% | -0.6× | — |
| SIGA | $218M | 9.5× | 2.6× | 2.3× | -31.8% | 68.6% | 24.6% | 11.7% | 11.7% | -6.4× | 25 |
| PYXS | $216M | — | — | 15.6× | -14.2% | 82.8% | -575% | -149% | -149% | — | 10 |
| NATR | $216M | 11.6× | 3.1× | 0.5× | 5.7% | 72.4% | 4.1% | 12.1% | 12.1% | -2.4× | 19 |
| AKBA | $196M | — | 2.4× | 0.8× | 47.5% | 83.3% | -2.3% | -16.4% | -6.6% | -5.5× | 27 |
| WHWK | $185M | — | — | 25.9× | -72.5% | 89.4% | -288% | -15.1% | -15.1% | — | 10 |
| MGNX | $153M | — | — | 1.0× | -0.3% | 100% | -49.9% | -134% | -134% | — | 18 |
| DERM | $146M | — | — | 2.4× | 10.2% | 66.2% | -18.5% | -35.9% | -20.0% | — | 4 |
| RNA | $141M | — | — | 7.5× | 72.1% | — | — | -40.5% | -40.5% | — | — |
| BGM | $127M | — | — | 3.4× | 51.1% | 16.6% | -52.6% | -5.1% | -5.1% | — | — |
Peers = companies sharing RNA's sector (Pharmaceutical Preparations) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
No positive operating income in the last three years, so there is no return on capital to compare against its cost.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2018 | not reported | -2769.9% | -2959.4% |
| FY2019 | not reported | -747.4% | -1066.6% |
| FY2020 | not reported | -652.4% | -653.5% |
| FY2021 | not reported | -1265.8% | -1265.4% |
| FY2022 | not reported | -1939.6% | -1886.3% |
| FY2023 | not reported | -2464.4% | -2219.9% |
| FY2024 | not reported | -3477.4% | -2957.7% |
| FY2025 | not reported | -3977.3% | -3650.4% |
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: tax_rate.
Fewer than three profitable years with a cash flow statement, so cash conversion cannot be judged.
No material counter-signal in the checked set: FCF / net income over 3 and 5 years, Sloan accruals, SBC as a share of revenue, SBC as a share of operating cash flow, SBC-adjusted free cash flow, free cash flow per diluted share, buybacks against SBC issued, capex vs depreciation, free cash flow against revenue, share count since the first year on file, cash conversion cycle (DSO, DIO, DPO), receivables growth against revenue growth.
Missing from our data, so excluded from this answer: 3 years of cash flow.
Debt is present but there is no positive EBITDA or no reported interest expense, so coverage cannot be measured.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
Missing from our data, so excluded from this answer: ebitda, interest_expense.
No positive free cash flow to discount, so the price cannot be expressed as a growth requirement.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: free_cash_flow.